What is Leerink Partnrs’ Forecast for TMO Q1 Earnings?

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities research analysts at Leerink Partnrs issued their Q1 2026 earnings estimates for Thermo Fisher Scientific in a report issued on Wednesday, April 23rd. Leerink Partnrs analyst P. Souda anticipates that the medical research company will earn $6.06 per share for the quarter. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific’s Q2 2026 earnings at $6.29 EPS, Q3 2026 earnings at $6.30 EPS, Q4 2026 earnings at $6.94 EPS and FY2026 earnings at $25.59 EPS.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.11 earnings per share.

A number of other equities analysts have also recently commented on TMO. Scotiabank dropped their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a report on Friday, April 25th. StockNews.com cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Friday, April 25th. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, April 24th. Argus decreased their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Morgan Stanley upped their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Five investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $610.27.

Thermo Fisher Scientific Stock Up 1.5 %

NYSE TMO opened at $427.56 on Monday. The stock has a 50 day moving average price of $482.87 and a 200-day moving average price of $524.80. Thermo Fisher Scientific has a one year low of $409.85 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a market capitalization of $161.40 billion, a P/E ratio of 25.87, a P/E/G ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.09%.

Insider Buying and Selling

In related news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,900 shares of company stock worth $13,106,062. 0.33% of the stock is owned by insiders.

Institutional Trading of Thermo Fisher Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in TMO. Nordea Investment Management AB lifted its holdings in Thermo Fisher Scientific by 23.6% in the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company’s stock worth $28,868,000 after acquiring an additional 10,606 shares during the last quarter. S.E.E.D. Planning Group LLC lifted its stake in Thermo Fisher Scientific by 6.2% during the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company’s stock valued at $5,528,000 after purchasing an additional 618 shares during the last quarter. Czech National Bank raised its position in shares of Thermo Fisher Scientific by 6.6% during the fourth quarter. Czech National Bank now owns 82,934 shares of the medical research company’s stock worth $43,145,000 after purchasing an additional 5,118 shares during the period. Douglas Lane & Associates LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 182,511 shares of the medical research company’s stock worth $94,948,000 after buying an additional 3,460 shares during the period. Finally, Granite Bay Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $4,758,000. Institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.